BGI Genomics Co Ltd (300676) - Net Assets

Latest as of September 2025: CN¥9.37 Billion CNY ≈ $1.37 Billion USD

Based on the latest financial reports, BGI Genomics Co Ltd (300676) has net assets worth CN¥9.37 Billion CNY (≈ $1.37 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.30 Billion ≈ $1.80 Billion USD) and total liabilities (CN¥2.93 Billion ≈ $428.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BGI Genomics Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥9.37 Billion
% of Total Assets	76.18%
Annual Growth Rate	40.98%
5-Year Change	53.87%
10-Year Change	192.53%
Growth Volatility	86.2

BGI Genomics Co Ltd - Net Assets Trend (2012–2024)

This chart illustrates how BGI Genomics Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is BGI Genomics Co Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for BGI Genomics Co Ltd (2012–2024)

The table below shows the annual net assets of BGI Genomics Co Ltd from 2012 to 2024. For live valuation and market cap data, see BGI Genomics Co Ltd (300676) market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥9.27 Billion ≈ $1.36 Billion	-7.32%
2023-12-31	CN¥10.00 Billion ≈ $1.46 Billion	-2.15%
2022-12-31	CN¥10.22 Billion ≈ $1.50 Billion	+8.29%
2021-12-31	CN¥9.44 Billion ≈ $1.38 Billion	+56.68%
2020-12-31	CN¥6.03 Billion ≈ $881.76 Million	+36.92%
2019-12-31	CN¥4.40 Billion ≈ $644.01 Million	+3.50%
2018-12-31	CN¥4.25 Billion ≈ $622.25 Million	-0.13%
2017-12-31	CN¥4.26 Billion ≈ $623.07 Million	+23.33%
2016-12-31	CN¥3.45 Billion ≈ $505.22 Million	+8.93%
2015-12-31	CN¥3.17 Billion ≈ $463.80 Million	+116.27%
2014-12-31	CN¥1.47 Billion ≈ $214.45 Million	+145.09%
2013-12-31	CN¥597.94 Million ≈ $87.50 Million	+297.65%
2012-12-31	CN¥150.37 Million ≈ $22.00 Million	--

Equity Component Analysis

This analysis shows how different components contribute to BGI Genomics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 6423.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥3.67 Billion	40.22%
Common Stock	CN¥415.82 Million	4.55%
Other Components	CN¥5.05 Billion	55.23%
Total Equity	CN¥9.13 Billion	100.00%

BGI Genomics Co Ltd Competitors by Market Cap

The table below lists competitors of BGI Genomics Co Ltd ranked by their market capitalization.

Company	Market Cap
OneStream, Inc. Class A Common Stock NASDAQ:OS	$2.44 Billion
Santos Brasil Participações S.A SA:STBP3	$2.45 Billion
Home Product Center Public Company Limited BK:HMPRO	$2.45 Billion
Meshek Energy-Renewable Energies Ltd TA:MSKE	$2.45 Billion
Triputra Agro Persada Tbk PT JK:TAPG	$2.44 Billion
West African Resources Ltd AU:WAF	$2.44 Billion
RH NYSE:RH	$2.44 Billion
Delek US Energy Inc NYSE:DK	$2.44 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BGI Genomics Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 9,859,237,734 to 9,134,857,139, a change of -724,380,595 (-7.3%).
Net loss of 902,690,856 reduced equity.
Dividend payments of 50,363,431 reduced retained earnings.
Share repurchases of 780,524,843 reduced equity.
Other factors increased equity by 1,009,198,535.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-902.69 Million	-9.88%
Dividends Paid	CN¥50.36 Million	-0.55%
Share Repurchases	CN¥780.52 Million	-8.54%
Other Changes	CN¥1.01 Billion	+11.05%
Total Change	CN¥-	-7.35%

Book Value vs Market Value Analysis

This analysis compares BGI Genomics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.80x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 21.84x to 1.80x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	CN¥1.83	CN¥39.94	x
2013-12-31	CN¥4.89	CN¥39.94	x
2014-12-31	CN¥4.64	CN¥39.94	x
2015-12-31	CN¥9.09	CN¥39.94	x
2016-12-31	CN¥9.29	CN¥39.94	x
2017-12-31	CN¥10.94	CN¥39.94	x
2018-12-31	CN¥10.41	CN¥39.94	x
2019-12-31	CN¥10.78	CN¥39.94	x
2020-12-31	CN¥14.80	CN¥39.94	x
2021-12-31	CN¥22.64	CN¥39.94	x
2022-12-31	CN¥24.59	CN¥39.94	x
2023-12-31	CN¥23.91	CN¥39.94	x
2024-12-31	CN¥22.15	CN¥39.94	x

Capital Efficiency Dashboard

This dashboard shows how efficiently BGI Genomics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -9.88%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -23.34%
• Asset Turnover: 0.31x
• Equity Multiplier: 1.37x
Recent ROE (-9.88%) is below the historical average (15.56%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	72.18%	10.28%	0.79x	8.86x	CN¥70.41 Million
2013	33.98%	12.97%	0.70x	3.74x	CN¥95.89 Million
2014	2.37%	2.48%	0.55x	1.73x	CN¥-90.47 Million
2015	8.47%	19.88%	0.34x	1.26x	CN¥-47.40 Million
2016	9.90%	19.44%	0.40x	1.26x	CN¥-3.29 Million
2017	9.60%	19.00%	0.41x	1.23x	CN¥-16.77 Million
2018	9.28%	15.24%	0.48x	1.26x	CN¥-29.85 Million
2019	6.41%	9.87%	0.47x	1.37x	CN¥-155.07 Million
2020	35.37%	24.89%	0.75x	1.89x	CN¥1.50 Billion
2021	15.68%	21.60%	0.47x	1.53x	CN¥529.70 Million
2022	7.97%	11.38%	0.49x	1.43x	CN¥-205.09 Million
2023	0.94%	2.14%	0.32x	1.38x	CN¥-893.02 Million
2024	-9.88%	-23.34%	0.31x	1.37x	CN¥-1.82 Billion

Industry Comparison

This section compares BGI Genomics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

Industry: Diagnostics & Research
Average net assets among peers: $5,333,781,031
Average return on equity (ROE) among peers: 16.64%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
BGI Genomics Co Ltd (300676)	CN¥9.37 Billion	72.18%	0.31x	$2.44 Billion
Berry Genomics Co Ltd (000710)	$2.33 Billion	-10.83%	0.37x	$516.80 Million
Zhejiang DiAn Diagnostics Co (300244)	$9.50 Billion	15.09%	1.22x	$1.77 Billion
Hangzhou Tigermed Consulting (300347)	$24.45 Billion	8.28%	0.21x	$5.96 Billion
Beijing Strong Biotechnologies Inc (300406)	$3.27 Billion	11.90%	0.41x	$1.09 Billion
Ningbo MedicalSystem Biotechnology Co Ltd (300439)	$2.52 Billion	7.88%	0.42x	$567.44 Million
Maccura Biotechnology Co Ltd (300463)	$4.54 Billion	21.06%	0.45x	$928.17 Million
Guangdong Hybribio Biotech Co Ltd (300639)	$501.67 Million	15.17%	0.15x	$573.30 Million
Amoy Diagnostics Co Ltd (300685)	$756.74 Million	16.75%	0.08x	$1.16 Billion
Shanghai Labway Clinical Laboratory Co Ltd (301060)	$130.79 Million	64.49%	1.52x	$605.42 Million

About BGI Genomics Co Ltd

SHE:300676 China Diagnostics & Research

Market Cap

$2.44 Billion

CN¥16.71 Billion CNY

Market Cap Rank

#5548 Global

#1134 in China

Share Price

CN¥39.94

Change (1 day)

-0.89%

52-Week Range

CN¥38.41 - CN¥59.25

All Time High

CN¥248.01